Logo image
Back
Oxcarbazepine therapy in very young children: a single-center clinical experience
Journal article   Peer reviewed

Oxcarbazepine therapy in very young children: a single-center clinical experience

Sanjeev V Kothare, Navid Mostofi, Divya S Khurana, Bashar Mohsem, Joseph J Melvin, Huntley H Hardison, Ignacio Valencia and Agustin Legido
Pediatric neurology, v 35(3)
Sep 2006
DOI: https://doi.org/10.1016/j.pediatrneurol.2006.03.003
PMID: 16939855
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Age Factors Anticonvulsants - administration & dosage Anticonvulsants - therapeutic use Carbamazepine - administration & dosage Carbamazepine - analogs & derivatives Carbamazepine - therapeutic use Child, Preschool Epilepsy - drug therapy Female Follow-Up Studies Humans Infant Male Retrospective Studies Treatment Outcome
Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children >or=4 years of age. The purpose of this retrospective chart review was to assess efficacy and tolerability of oxcarbazepine in children <or=4 years of age. A single-center retrospective chart review of patients <or=4 years old with epilepsy receiving oxcarbazepine between 2001 to 2004 was conducted. Twenty patients (male = 13, female = 7; ages 6-45 months [mean age 22.8 months]) who received oxcarbazepine were identified. Seizure types included partial onset (75%), symptomatic generalized (15%), and other (n = 2, 10%). Oxcarbazepine doses ranged between 14-71 mg/kg/day (mean dose: 36.5 mg/kg/day). Oxcarbazepine was prescribed as monotherapy in 15 patients and as first-line therapy in 73% patients. Overall, 70% experienced a significant reduction in seizures, and 50% became seizure-free while receiving oxcarbazepine. Transient drowsiness was reported in 20% of patients during dose escalation. No adverse events were observed in children <2 years old. The findings from this small series suggest that oxcarbazepine as monotherapy and adjunctive therapy may be effective and well tolerated in pediatric patients <or=4 years of age.

Metrics

12 Record Views
11 citations in Web of Science
17 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Clinical Neurology
Pediatrics
Logo image